NASH contender CymaBay runs into trouble as mid-stage data disappoint
A snapshot of negative data from an ongoing 52-week mid-stage NASH study evaluating CymaBay Therapeutics’ lead drug has triggered alarm, after the experimental liver drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.